Restoration of the antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus by delivery of engineered thymidylate kinase to T cells

Journal of General Virology

Volumn 89, Issue 7, 2008, Pages 1672-1679

  Lavie, Arnon ^a   Su, Ying ^a   Ghassemi, Mahmood ^a   Novak, Richard M ^a   Caffrey, Michael ^a   Sekulic, Nikolina ^a   Monnerjahn, Christian ^b   Konrad, Manfred ^b   Cook, James L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOSIDE MONOPHOSPHATE KINASE; THYMIDYLATE KINASE; TRANSACTIVATOR PROTEIN; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAG PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL TRANSPORT; CONCENTRATION RESPONSE; DRUG EFFICACY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ENGINEERING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; RNA TRANSLATION; T LYMPHOCYTE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENETICS; KINETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE; VIROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DRUG RESISTANCE, VIRAL; HIV; HIV CORE PROTEIN P24; HUMANS; KINETICS; MODELS, MOLECULAR; NUCLEOSIDE-PHOSPHATE KINASE; PROTEIN STRUCTURE, TERTIARY; VIRUS REPLICATION; ZIDOVUDINE;

EID: 48849091390     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.2008/000273-0     Document Type: Article

References (29)

1. Agarwal, R. P. & Mian, A. M. (1991). Thymidine and zidovudine metabolism in chronically zidovudine-exposed cells in vitro. Biochem Pharmacol 42, 905-911.
2. Arion, D. & Parniak M. A. (1999). HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resist Updat 2, 91-95.
3. Arion, D., Kaushik, N., McCormick S., Borkow, G. & ParniaK M. A. (1998). Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37, 15908-15917.
4. Brundiers, R, Lavie, A., Veit, T., Reinstein, J., Schlichting, I., Ostermann, N., Goody, R. S. & Konrad, M. (1999). Modifying human thymidylate kinase to potentiate azidothymidine activation. J Biol Chem 274, 35289-35292.
5. Efthymiadis, A., Briggs, L. J. & Jans, D. A. (1998). The HIV-1 Tat nuclear localization sequence confers novel nuclear import properties. J Biol Chem 273, 1623-1628.
6. Foley, G. E., Lazarus, H., Farber, S., Uzman, B. G., Boone, B. A. & McCarthy, R. E. (1965). Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18, 522-529.
7. Fridland, k, Connelly, M. C. & Ashmun, R. (1990). Relationship of deoxynucleotide changes to-inhibition of DNA synthesis induced by the antiretroviral agent 3′-azido-3′-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CFM). Mol Pharmacol 37, 665-670.
8. Furman, P. A., Fyfe, J. A., St. Clair, M. H., Weinhold, K, Rideout, J. L., Freeman, G. A., Lehrman, S. N., Bolognesi, D. P., Broder, S. & other authors (1986). Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 83, 8333-8337.
9. Jong, A. Y. & Campbell, J. L. (1984). Characterization of Saccharomyces cerevisiae thymidylate kinase, the CDC8 gene product. General properties, kinetic analysis, and subcellular localization. J Biol Chem 259, 14394-14398.
10. Junker, U., Baker, J., Kalfoglou, C. S., Veres, G, Kaneshima, H. & Bohnlein, E. (1997). Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 13, 1395-1402.
11. Larder, B. A. & Kemp, S. P. (1989). Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155-1158.
12. Lavie, A., Vetter, I. R., Konrad, M., Goody, R. S., Reinstein, J. & Schlichting, I. (1997). Structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation. Nat Struct Biol 4, 601-604.
13. Lavie, A., Ostermann, N., Brundiers, R., Goody, R. S., Reinstein, J., Konrad, M. & Schlichting, I. (1998). Structural basis for efficient phosphorylation of 3′-azidothymidine monophosphate by Escherichia coli thymidylate kinase. Proc Natl Acad Sci U S A 95, 14045-14050.
14. Lowe, S. H., Prins, J. M. & Lange, J. M. (2004). Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome. Neth J Med 62, 424-440.
15. Meier, C., Lorey, M., De Clercq, E. & Balzarini, J. (1998). Cyclosal-2′,3′-dideoxy-2′,3′-didehydrothymidine monophosphate (cyclosal-d4TMP) - synthesis and antiviral evaluation of a new d4TMP delivery system. J Med Chem 41, 1417-1427.
16. Meyer, P. R., Matsuura, S. E., Mian, A. M., So, A. G. & Scott, W. A. (1999). A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 4, 35-43.
17. Nara, P. L. & Fischinger, P. J. (1988). Quantitative infectivity assay for HIV-1 and -2. Nature 332, 469-470.
18. Nara, P. L., Hatch, W. C., Dunlop, N. M., Robey, W. G., Arthur, L. O., Gonda, M. A. & Fischinger, P. J. (1987). Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses 3, 283-302.
19. Ostermann, N., Lavie, A., Padiyar, S., Brundiers, R., Veit, T., Reinstein, J., Goody, R. S., Konrad, M. & Schlichting, I. (2000a). Potentiating AZT activation: structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP. J Mol Biol 304, 43-53.
20. Ostermann, N., Schlichting, I., Brundiers, R., Konrad, M., Reinstein, J., Veit, T., Goody, R. S. & Lavie, A. (2000b). Insights into the phosphoryltransfer mechanism of human thymidylate kinase gained from crystal structures of enzyme complexes along the reaction coordinate. Structure 8, 629-642.
21. Qian, M., Bul, T., Ho, R. J. & Unadkat, J. D. (1994). Metabolism of 3′-azido-3′-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells. Biochem Pharmacol 48, 383-389.
22. Sarafianos, S. G., Das, K., Clark, A. D., Jr, Ding, J., Boyer, P. L., Hughes, S. H. & Arnold, E. (1999). Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc Natl Acad Sci U S A 96, 10027-10032.
23. Schwarze, S. R. & Dowdy, S. F. (2000). In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 21, 45-48.
24. Schwarze, S. R., Ho, A., Vocero-Akbani, A. & Dowdy, S. F. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285, 1569-1572.
25. Shaw, G. M., Hahn, B. H., Arya, S. K., Groopman, J. E., Gallo, R. C. & Wong-Staal, F. (1984). Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 226, 1165-1171.
26. Tkachenko, A. G., Xie, H., Liu, Y., Coleman, D., Ryan, J., Glomm, W. R., Shipton, M. K., Franzen, S. & Feldheim, D. L. (2004). Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem 15, 482-490.
27. Veal, G. J. & Back, D. J. (1995). Metabolism of zidovudine. Gen Pharmacol 26, 1469-1475.
28. Wagner, C. R., Iyer, V. V. & McIntee, E. J. (2000). Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med Res Rev 20, 417-451.
29. Wöhrl, B. M., Loubiere, L., Brundiers, R., Goody, R. S., Klatzmann, D. & Konrad, M. (2005). Expressing engineered thymidylate kinase variants in human cells to improve AZT phosphorylation and human immunodeficiency virus inhibition. J Gen Virol 86, 757-764.